Chronic insomnia is defined as a persistent difficulty with sleep initiation maintenance or non-restorative sleep. The therapeutic standard of care for this condition is treatment with gamma-aminobutyric acid (GABA) A receptor modulators, which promote sleep but are associated with a panoply of side effects, including cognitive and memory impairment. Dual orexin receptor antagonists (DORAs) have recently emerged as an alternative therapeutic approach that acts via a distinct and more selective wake-attenuating mechanism with the potential to be associated with milder side effects. Given their distinct mechanism of action, the current work tested the hypothesis that DORAs and GABA A receptor modulators differentially regulate neurochemical pathways associated with differences in sleep architecture and cognitive performance induced by these pharmacological mechanisms. Our findings showed that DORA-22 suppresses the release of the wake neurotransmitter histamine in the lateral hypothalamus, prefrontal cortex, and hippocampus with no significant alterations in acetylcholine levels. In contrast, eszopiclone, commonly used as a GABA A modulator, inhibited acetylcholine secretion across brain regions with variable effects on histamine release depending on the extent of wakefulness induction. In normal waking rats, eszopiclone only transiently suppressed histamine secretion, whereas this suppression was more obvious under caffeine-induced wakefulness. Compared with the GABA A modulator eszopiclone, DORA-22 elicits a neurotransmitter profile consistent with wake reduction that does not impinge on neurotransmitter levels associated with cognition and rapid eye movement sleep.
The sleep-wake cycle is the result of a balanced integration of inhibitory and excitatory signals, which converge into the arousal and vigilance state control centers in the central nervous system (CNS). One of the main neuronal networks responsible for sleep-wake regulation comprises the monoaminergic neurons, which display well-characterized secretory activities and include the vigilance state-gating noradrenergic locus coeruleus and serotoninergic dorsal and median raphe nuclei, and the arousal-promoting histaminergic tuberomammillary nuclei (TMN) (Saper et al. 2005) . The wake-promoting monoaminergic neurons receive their input from the orexin-secreting peptidergic neurons in the lateral hypothalamus (LH). The TMN is the arousal center from which all histaminergic neurons arise, with projections to both the LH and the prefrontal cortex (PFC) (Panula et al. 1984; Lin et al. 1988) . The neurocircuitry of orexin neurons directly implicates them in the regulation of the release of histamine, as one of their primary projections extends to the TMN (Eriksson et al. 2001; Sakurai 2007) , where the orexin 2 receptor (OX 2 R) is highly expressed; specific orexin signaling through this receptor has been shown to be associated with wakefulness (Marcus et al. 2001) . Therefore, it is postulated that modulation of orexin receptors localized in the TMN produces a significant change in histamine levels. Conversely, the major inhibitory, sleep-promoting signal originates from the gamma-aminobutyric acid (GABA A )-secreting ventrolateral preoptic nucleus (VLPO). Historically, clinically used sleep agents have exerted their sedative effects through the potentiation of GABA A neurotransmission and suppression of the stimulatory monoaminergic pathways. Such agents include positive allosteric modulators of GABA A receptors that consolidate the inhibitory influence of GABA A signaling and induce sleep (Mohler et al. 2002) . However, GABA A signaling plays a significant role in a multitude of physiological and behavioral effects beyond sedation, including cognitive impairment, motor dysfunction, sleepwalking, and next-day effects (Roth and Roehrs 1992; Roehrs et al. 1994; Roehrs and Roth 2012; Gunja 2013) . Eszopiclone (Lunesta â , Sunovion Pharmaceuticals Inc., Marlborough, MA, USA) is one of the most widely prescribed GABA A receptor-modulating soporifics, and is characterized by a side-effect profile typical of this mechanism (Danjou et al. 1999) .
The orexins are two neuropeptides acting at two G proteincoupled receptors, orexin 1 receptor (OX 1 R) and OX 2 R. Orexin levels exhibit diurnal variation with increased levels corresponding to times of wakefulness and decreased levels during sleep in both human subjects (Grady et al. 2006) and rodents (Taheri et al. 2000) . Multiple lines of evidence support the importance of orexin signaling in the sustenance of arousal. During the wake phase in rats, orexin neurons are activated as indicated by the increase in the expression of the immediate early gene Fos and elevation of orexin levels in the cerebrospinal fluid (CSF) (Estabrooke et al. 2001; Yoshida et al. 2001) , and similar effects are observed after the administration of the wake-promoting drug modafinil (Chemelli et al. 1999) . Artificial activation of orexinergic neurons by photostimulation leads to a hyperaroused state in mice (Adamantidis et al. 2007; Carter et al. 2009 ). Furthermore, intracerebroventricular injections of orexin A or orexin B in rats during their sleep phase extends the time they spend awake (Date et al. 1999) .
Because of their central role in wakefulness modulation, orexin receptors constitute an attractive approach for treating sleep and arousal impairments. Small-molecule, non-peptide OX 2 R agonists have recently emerged as potential, powerful arousal-sustaining agents. Mice treated intracerebroventricularly with these molecules showed an increase in their wake time in a dose-dependent fashion (Nagahara et al. 2015) . Alternatively, small-molecule inhibitors of these receptors exhibit potent sleep-promoting properties (Winrow and Renger 2014) . Dual orexin receptor antagonists (DORAs) target both OX 1 R and OX 2 R, and have shown efficacy in promoting sleep in rodents and in treating insomnia in humans (Brisbare-Roch et al. 2007; Winrow et al. 2011; Fox et al. 2013; Michelson et al. 2014; Herring et al. 2016) . Unlike GABA A receptors, which are broadly active throughout the CNS, orexin receptors show a restricted activity to arousal-promoting and vigilance state-gating circuits. Therefore, blockade of the orexin pathway through its receptors offers a more specifically targeted approach to treat sleep dysregulation, which in turn might translate into an improved safety profile relative to the current standards of care . Numerous studies in animals support the latter hypothesis. Ramirez et al. (2013) showed that, in rats, DORAs almorexant and DORA-12 do not induce motor deficits that are associated with eszopiclone. Similarly, Uslaner et al. (2013) demonstrated that the sleep-inducing properties of DORA-22, a potent structurally distinct DORA , were not accompanied by the cognition-disruptive effects that commonly emerge with eszopiclone at and below sleep-promoting exposures. Additionally, DORA-22 exhibited robust sleep-promoting properties in rodents by inducing an electroencephalogram (EEG) signature that more closely approximated that of normal sleep compared with eszopiclone, which suppressed rapid eye movement (REM) sleep .
The present work uses a representative DORA (DORA-22) and a representative GABA A receptor modulator (eszopiclone) to test the hypothesis that these sleep-promoting mechanisms differentially regulate neurochemical changes associated with previously described differences in sleep architecture and cognitive performance. We used rats under conditions where histamine and acetylcholine levels are high, namely the sleep-waking transition and caffeine-induced arousal during sleep, the latter emulating the conditions associated with insomnia. We examined the effect of DORA administration relative to eszopiclone on neurotransmitter release in the LH, PFC, and hippocampus (Hip) areas, which are known to regulate wake, cognitive functions, and sleep architecture.
Methods

Animals
All animal care and testing procedures were conducted in compliance with the National Research Council's 'Guide for the Care and Use of Laboratory Animals' and the Animal Welfare Act, and were approved by the Merck Animal Care and Use Committee. The results of the study were reported according to the Animal Research: Reporting In Vivo Experiments (ARRIVE) guidelines. This study was conducted using male Sprague-Dawley rats (240-310 g; 9 weeks of age; Taconic Farms Inc., Hudson, NY, USA). The animals were singly housed for all studies, with food and water available ad libitum. The animals were acclimated to a 12 : 12 h light : dark for 2 weeks.
Compounds and formulations
All pharmacological agents, DORA-22, and eszopiclone were synthesized by Merck chemists and diluted in 20% VitE-TPGS to a dose volume of 2 mL/kg to be administered orally (per os, p.o.). Caffeine (Sigma Co., Cream Ridge, NJ, USA) was diluted in 0.5% methylcellulose to a dose volume of 2 mL/kg to be administered p.o.
Surgical procedure
During the surgical implantation of the intracerebral guide cannulae in the rats' brains, 1-5% isoflurane in oxygen was used as anesthetic (Isothesia, Butler Schein Animal Health, Dublin, OH, USA) and flunexin was administered subcutaneously as pre-operative analgesic (2.5 mg/kg) in order to minimize pain and discomfort. If needed, flunexin was also administered postoperatively after consultation with a veterinarian. Rats were placed in a stereotaxic frame, and intracerebral guide cannulae (CMA 12) were stereotaxically implanted into the brain to allow positioning of the dialysis probe in the dorsal Hip (AP À4.4 mm, ML À2.5 mm relative to bregma, and DV À2.0 mm relative to skull surface [+2 mm for probe membrane]), PFC (AP +3.0 mm, ML À0.6 mm relative to the medial line, and DV À1.3 mm relative to skull surface [+2 mm for probe membrane]), or LH (AP À1.8 mm, ML À1.8 mm relative to bregma, and DV À7.0 mm relative to skull surface, [+2 mm for probe membrane]) and fixed in place with two anchor screws and dental cement (Watson and Paxinos 2006) . After recovery from anesthesia, the animals were returned to the housing facility until the microdialysis procedure was conducted, and they were monitored for pain and distress throughout recovery and experimental analysis. Probe placement was confirmed by post hoc histological analysis, and those subjects deviating by more than 0.5 mm from the target placement (see Supporting Information Figure illustrating probe placement) were excluded from analysis.
In vivo microdialysis and sample collection On the day of probe insertion, the rats were randomly assigned to control and treatment groups using an online tool, and transferred to a swivel bowl-tether microdialysis system (Instech Laboratories, Plymouth Meeting, PA, USA) where they were able to move freely during dialysis and had access to food and water. Microdialysis probes (CMA 12) (3 mm, dorsal Hip and PFC; 2 mm LH) were perfused at a rate of 1.0 lL/min with artificial CSF (147 mM NaCl, 2.7 mM KCl, 1.2 mM CaCl 2 , and 0.85 mM MgCl 2 [Harvard Apparatus, Holliston, MA, USA]) and inserted through the guide cannula. The animals were allowed to habituate and stabilize overnight prior to sample collection. For each experiment, rats were evenly assigned to experimental and control groups (15 rats/group) based on previous studies indicating an effective group size of n ≥ 6 (Murillo- Rodriguez et al. 2003; Walker et al. 2013; unpublished results) . Up to 10 animals evenly distributed among experimental and control groups were assessed simultaneously in single daily recording sessions such that final group n's ranged from 8 to 15 subjects may be reached within subsequent recording sessions not exceeding a total of five consecutive daily recording sessions. Samples were collected every 30 min for 6 h into a refrigerated fractional collector, transferred to dry ice and stored at À80°C until analysis. Criteria for excluding an animal subject's results included probe misplacement (> 2 mm) in post hoc morphological analysis or the inability to collect 2 or more 30 min time point samples from which detectable analyte could be measured by ultra-high-pressure liquid chromatography/tandem mass spectrometry (UPLC-MS/MS).
Dark (active) phase experiments were performed under dim red light conditions and laboratory access was limited to personnel performing these studies to minimize impact to circadian phase. Baseline samples were collected for 2 h prior to lights off. Drugs were administered orally 1 h after dark phase onset, and samples were collected for an additional 3-4 h in the dark.
During caffeine stimulation experiments (inactive phase), baseline samples were collected for 2 h prior to administration of DORA-22 (30 mg/kg) or eszopiclone (30 mg/kg) co-dosed orally with caffeine (30 mg/kg), and samples were collected for 4 h after administration.
Histamine and acetylcholine analysis
The levels of histamine and acetylcholine were determined using UPLC-MS/MS. Dialysate samples were directly injected onto a Kinetex hydrophilic interaction liquid chromatography column (2.1 9 100 mm, 2.6 lm; Phenomenex, Torrance, CA, USA), and analytes were resolved using a gradient of mobile phase A (20 mM ammonium formate; 0.2% formic acid) and mobile phase B (acetonitrile) at a flow rate of 0.45 mL/min (10-70% Buffer A gradient over 1.25 min) followed by a 1.25 min wash in 70% Buffer A to elute late peaks. MS/MS detection was performed using an API4000 mass spectrometer (AB Bioscience Instruments, Boston, MA, USA); histamine and acetylcholine were detected at the respective mass-to-charge ratio (m/z) transitions of 112.1/95.3 and 146/87. Deuterated histamine (d4-histamine; m/z 116.1/99.3) and deuterated acetylcholine (d4-acetylcholine; m/z 150/91) were used as internal standards. The level of the analyte of interest was given by the ratio of the area of its extracted ion chromatogram relative to d4 deuterated internal standard. In darkness stimulation experiments, the average baseline level was calculated as the mean of the first four samples collected 2 h prior to lights off. In caffeine stimulation studies, the average baseline was the mean of the first four time points before dosing.
Statistical analysis
The percent change in analyte level at each collection time point was calculated relative to the average baseline (results are expressed as percent change from baseline since microdialysis membrane recovery varies with probe insertion). Values were not corrected to account for the efficiency of recovery across the microdialysis membrane. Area under the curve values were calculated as the integration of percent change from vehicle over 4 h following treatment and analyzed for significance by one-way analysis of variance (ANOVA) followed by Tukey's multiple comparisons test using GraphPad Prism version 7.00 for Windows (GraphPad Software, La Jolla California USA, www.graphpad.com). All graphed values are presented as mean AE standard error.
Results
Differential effects of DORA-22 and eszopiclone on neurotransmitter levels during sleep-wake transitions The transition of rats to the active physical state is translated on the neurochemical level into an induction of histamine and acetylcholine in the LH, PFC, and Hip. In the considered brain regions, the two neurotransmitters regulate arousal and cognition, respectively. The effects of DORA-22 versus eszopiclone on the regulation of histamine and acetylcholine levels were examined. During the inactive-to-active phase transition, DORA-22 at both 10 and 30 mg/kg doses, significantly reduced histamine levels in the LH (Fig. 1a) Acetylcholine modulates neurons in the Hip playing an important role in cognition (Blandina et al. 2004) . Levels of acetylcholine were elevated 30 min following the inactiveto-active phase transition (Fig. 2) . Administration of DORA-22 at 3 and 10 mg/kg, treatments previously demonstrated to induce sleep (Uslaner et al. 2013) , did not have a significant inhibitory effect on acetylcholine levels during the inactiveto-active phase transition (Fig. 2a) (F (2,6) = 4.17, p > 0.05). Conversely, administration of eszopiclone at 3 and 10 mg/kg significantly reduced acetylcholine levels during this period (Fig. 2b) (F (2,6) = 18.97, p < 0.05). In summary, during the sleep-wake transition, DORA-22 inhibited the release of the wake neurotransmitter histamine in the LH, PFC, and dorsal Hip with no or transient change in acetylcholine levels in the Hip. However, a contrasting effect was observed with eszopiclone, which failed to induce significant changes in histamine levels while significantly suppressing acetylcholine secretion.
Differential effects of DORA-22 and eszopiclone on caffeine-induced neurotransmitter levels To further explore the role of DORA-22 and eszopiclone on histamine and acetylcholine, we examined the neurochemical effects of these drugs following caffeine stimulation. As expected, histamine and acetylcholine levels were significantly increased by administration of the alerting agent caffeine (Fig. 3) . To evaluate the potential of DORA-22 and eszopiclone to modulate caffeine-induced histamine and acetylcholine levels, both compounds were administered at similarly maximal efficacious doses (30 mg/kg) for these experiments (Fig. 3) . While caffeine significantly induced histamine levels during the inactive phase in all three brain regions, DORA-22 attenuated the caffeine-induced histamine levels (LH: F (3,32) = 27.42, p < 0.05; PFC: F (3,32) = 13.53, p < 0.05; Hip: F (3,32) = 13.26, p < 0.05; one-way ANOVA, Tukey's multiple comparisons test) without significantly impacting the levels of caffeine-induced acetylcholine in any of the brain regions examined (Fig. 4) (LH: F (3,32) = 30.61, p = 0.6464; PFC: F (3,32) = 15.7, p = 0.3954; Hip: F (3,32) = 15.78, p = 0.7240; one-way ANOVA, Tukey's multiple comparisons test). This lack of effect on acetylcholine levels by DORA-22 is remarkable given that the dose used in this experiment is 30-fold above the 1 mg/kg threshold dose required for sleep-promoting effects in these animals (Uslaner et al. 2013) .
In contrast to DORA-22, eszopiclone significantly reversed both caffeine-induced histamine and acetylcholine levels in the LH (Figs 3a and 4a; F 
Discussion
The purpose of this study was to better understand the mechanism of action of the sleep-promoting orexin receptor antagonist DORA-22, and differentiate it from eszopiclone, a representative GABA A receptor modulator, with respect to regulation of neurotransmitter levels in different regions of the brain that mediate arousal and cognitive functions. Given the role of histamine in mediating wakefulness, and the importance of orexin signaling in controlling histamine release from neurons originating from the TMN (Eriksson et al. 2001) , the suppressive effects of DORA-22 on histamine secretion are consistent with the hypnotic properties of orexin signaling blockade. Beyond histaminergic signaling, however, DORA-22 and eszopiclone exhibited contrasting effects on neurotransmitter levels. These changes included differential inhibition of acetylcholine levels by GABA A potentiation, indicating an uncoupling from histaminergic signaling associated with decreased arousal. Additionally, these findings suggest a rationale for the clinically observed suppression of REM sleep and cognitive impairment including amnestic side effects associated with GABA A modulation.
To model arousal, we assessed rats as they transitioned from the light to dark phase, taking advantage of the normal progression into the active period. Consistent with previous reports, the light-to-dark transition produced a significant surge in histamine levels in the LH, PFC, and dorsal Hip (Dugovic et al. 2009 ). In accordance with the hypothesized mechanism, DORA-22 significantly reduced histamine levels across the three brain regions at 10 and 30 mg/kg doses previously reported to promote sleep ). The inhibition pattern was very similar in the LH and PFC. Interestingly, despite the importance of histamine in regulating the normal sleep-wake cycle, eszopiclone had only transient effects on this neurotransmitter in the LH, PFC, and dorsal Hip, thereby highlighting the inability of this GABA A modulator to produce a robust modulation of histamine levels during the light-to-dark transition. Considering that GABA release mediates widespread neuronal inhibition in addition to monoaminergic neurons downstream of the VLPO, the sedative effects of eszopiclone are likely because of greater non-selective suppression of CNS activity.
In an attempt to more closely approximate the insomniac state, wakefulness was induced during the inactive phase using caffeine (Paterson et al. 2009 ). This treatment induced an arousal signature as confirmed by increases in histamine and acetylcholine levels in the LH, PFC, and dorsal Hip. DORA-22 significantly inhibited caffeine-induced histamine release in all three regions. Eszopiclone, which only showed a transient attenuation of histamine release during the lightto-dark transition, elicited a broad and significant suppression of caffeine-induced histamine increase. Compared with DORA-22, eszopiclone displayed a differential modulation of histamine depending on the level of arousal-induced histamine increase. These results suggest that under normal wake conditions, orexinergic input may be of greater impact on histamine release relative to a reduction in GABA A influence.
In contrast, during caffeine stimulation, histamine release is likely supported by weak but synergistic pathways, including the anxiety-induced signaling acting in parallel to the wakefulness signaling mediated by the orexin system (Privou et al. 1998; Alsene et al. 2003; John et al. 2014) . In addition, caffeine indirectly forces a wake signature in the sleep state by blocking adenosine A2A receptors and abrogating their downstream sleep-promoting effects (Boutrel and Koob 2004; Huang et al. 2005) . The use of GABA A modulators not only may suppress both the normal wake signaling system through enhancement of suppression via the VLPO, but also likely reduces the parallel arousal signaling via the anxiety pathway induced by caffeine and mediated through other signaling via the thalamocortical and limbic systems. The discrepancy in robustness of histamine induction between natural arousal and caffeine-induced hyperarousal is such that the transient effects of eszopiclone on histamine secretion are able to elicit a greater inhibitory effect under the condition where parallel arousal pathways are converging on histamine release and the broad action of GABA A -mediated inhibition is more effective because of non-sleep circuit-specific signaling. Owing to its direct action at the TMN through specific antagonism of orexin receptors, DORA-22 is able to suppress histamine under both conditions of wakefulness. The downstream mechanisms mediating histaminergic-induced arousal, however, are likely more complex than direct cortical projections and include histamine-induced acetylcholine release from basal forebrain (Zant et al. 2012) , GABA regulation of orexin influence on TMN activity and GABAergic influences from TMN neurons themselves that may provide fine tuning and prevention of overactivation in striatal and cortical regions (Yu et al. 2015) .
Acetylcholine is implicated in various brain functions and plays a major role in the regulation of memory and cognition in the Hip and PFC, respectively (Blandina et al. 2004) , and is also important for the onset of REM sleep (Shiromani et al. 1987) . For this reason, and in order to further distinguish the mechanism of action of DORA-22 and eszopiclone, we assessed the effects of the two compounds on acetylcholine in different brain regions that are linked to sleep and cognitive function. Although eszopiclone profoundly reduced acetylcholine levels, DORA-22 had little or no impact on normal wake phase or caffeine-induced acetylcholine levels (Figs 2 and 4) . A comparative study assessing the effects of DORA-22 (3, 10, and 30 mg/kg) versus eszopiclone (0.3, 1, 3, and 10 mg/kg) on memory and cognition was previously reported (Uslaner et al. 2013) . DORA-22 exhibited a wide therapeutic margin with sleeppromoting doses as low as 1 mg/kg and cognition-disruptive doses starting at 30 mg/kg. Conversely, the sedative properties of eszopiclone took effect at 6 mg/kg, with cognitive deficits emerging at subsleep-promoting doses (e.g. 1 mg/kg) (Uslaner et al. 2013) ,. Differential regulation is also likely responsible for the differential alteration of EEG spectral frequencies induced by GABA A modulators (eszopiclone and zolpidem) relative to DORA-22 in rats. GABA A modulators substantially and dose dependently altered EEG spectral frequencies across all sleep stages including REM. In contrast, DORA-22 effects on the spectral profile were negligible and were only observed during REM stage at the highest dose tested . In view of our current data on effects on acetylcholine release in Hip and PFC, the higher thresholds for eliciting cognitive impairment and REM sleep suppression with DORA-22 relative to eszopiclone may be a consequence of their differential anticholinergic activity.
The finding that DORA-22 attenuates histamine levels while not similarly affecting acetylcholine levels in dorsal hippocampus represents a potential dissociation of function for these neurotransmitters in cognition and memory. In addition to cortical arousal, histamine tone (specifically through H 1 receptor signaling in the CA1 region of the hippocampus) appears involved in cognitive function including fear memory, and complements acetylcholine function in learning and memory (Blandina et al. 2004; Fabbri et al. 2016) . The potential dissociation exhibited orexin receptor inhibition relative to GABA A modulation and may represent differential impact on histamine/GABA and acetylcholine/GABA co-release to shift the balance of complementary histamine and acetylcholine function (Blandina et al. 2004; Eriksson et al. 2004; Yu et al. 2015) . Indeed, orexins applied to adult mouse hippocampal slices induce state-dependent long-term potentiation at Schaffer collateral-CA1 synapses, but long-term depression in juvenile slices, effects that appear mediated through OX 1 R and differential activation of serine/ threonine and tyrosine kinases (Selbach et al. 2010) . The hippocampal histamine/acetylcholine dissociation may result from a shift in the bistable excitation/ disinhibition balance mediated differentially by orexin and GABA A modulation to affect hippocampal information processing (Wu et al. 2002; Selbach et al. 2004) . Future work employing higher resolution approaches (e.g. optogenetics, chemogenetics) will undoubtedly define these interacting pathways further.
As the roles for OX 1 R and OX 2 R in the regulation of arousal and vigilance state control become more clearly defined, the impact of specific neurochemical changes associated with their individual activities will undoubtedly become better understood. OX 2 R is selectively expressed in histaminergic neurons of the TMN and is thought to drive orexin-dependent arousal since narcoleptic symptoms are associated with genetic loss of this receptor in dogs and mice (Lin et al. 1999; Willie et al. 2003) and selective OX 2 R inhibition is sufficient to promote sleep in animal models and humans (Dugovic et al. 2009; Morairty et al. 2012; Bonaventure et al. 2015; Gotter et al. 2016) . In fact, sleep-promoting effects of DORAs are nearly absent in OX 2 R knockout mice (Mang et al. 2012) . The impact of OX 1 R inhibition, however, is less clear. One study (Dugovic et al. 2009 ) suggested that cortical dopamine induction associated OX 1 R inhibition had the potential to attenuate the sleep promotion by OX 2 R antagonism while others have found greater sleep promotion at given OX 2 R occupancies (Morairty et al. 2012; Gotter et al. 2016) . The selective expression of OX 1 R in locus coeruleus, a brainstem nuclei involved in the regulation of REM sleep, may suggest selective OX 2 R antagonism could preferentially promote sleep without REM. Studies with OX 2 R-selective antagonists, however, have shown either a trend toward increased REM sleep that did not reach significance in rats (Bonaventure et al. 2015) or significant increases in rodent models and humans (Morairty et al. 2012; Gotter et al. 2016) . A greater understanding of the neurochemical pathways activated by these receptors using selective antagonists and agonists will further our understanding of the roles of OXRs in sleep/wake regulation.
In summary, our results describe differential neurotransmitter modulation by DORA-22 relative to the GABA A modulator eszopiclone that may underlie differences in previously observed sleep architecture, cognition and motor coordination. With DORAs such as DORA-22, the antagonism of orexin receptors localized to sleep-specific circuitry neurons appears to elicit the physiological histamine/acetylcholine neurotransmitter profiles reminiscent of non-therapeutically treated sleep. In contrast, eszopiclone modulation of the broad GABA A receptor network did not profoundly inhibit levels of the wake neurotransmitter histamine, while potent anticholinergic effects that had the potential to impact cognitive impairment and REM sleep suppression were observed.
